首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   114篇
  免费   9篇
  国内免费   3篇
儿科学   2篇
妇产科学   6篇
基础医学   11篇
临床医学   6篇
内科学   55篇
神经病学   2篇
特种医学   1篇
外科学   9篇
综合类   18篇
预防医学   9篇
药学   4篇
中国医学   2篇
肿瘤学   1篇
  2023年   3篇
  2022年   4篇
  2021年   5篇
  2020年   5篇
  2019年   5篇
  2018年   3篇
  2016年   9篇
  2015年   4篇
  2014年   14篇
  2013年   11篇
  2012年   7篇
  2011年   13篇
  2010年   7篇
  2009年   7篇
  2008年   9篇
  2007年   12篇
  2006年   4篇
  2005年   3篇
  2004年   1篇
排序方式: 共有126条查询结果,搜索用时 15 毫秒
121.

Ethnopharmacology relevance

Adipocytes are major tissues involved in glucose uptake second to skeletal muscle and act as the main adipocytokines mediator that regulates glucose uptake mechanism and cellular differentiation. The objective of this study were to examine the effect of the SDF7, which is a fraction consists of four flavonoid compounds (quercetin: p-coumaric acid: luteolin: apigenin=8: 26: 1: 3) from Scoparia dulcis Linn., on stimulating the downstream components of insulin signalling and the adipocytokines expression on different cellular fractions of 3T3-F442a adipocytes.

Material and methods

Morphology and lipid accumulation of differentiated 3T3-F442a adipocytes by 100 nM insulin treated with different concentrations of SDF7 and rosiglitazone were examined followed by the evaluation of glucose uptake activity expressions of insulin signalling downstream components (IRS-1, PI3-kinase, PKB, PKC, TC10 and GLUT4) from four cellular fractions (plasma membrane, cytosol, high density microsome and low density microsome). Next, the expression level of adipocytokines (TNF-α, adiponectin and leptin) and immunoblotting of treated 3T3-F442 adipocytes was determined at 30 min and 480 min. Glucose transporter 4 (GLUT4) translocation of 3T3-F442a adipocytes membrane was also determined. Lastly, mRNA expression of adiponectin and PPAR-γ of 3T3-F442a adipocytes were induced and compared with basal concentration.

Results

It was found that SDF7 was able to induce adipocytes differentiation with great extends of morphological changes, lipid synthesis and lipid stimulation in vitro. SDF7 stimulation of glucose transport on 3T3-F442a adipocytes are found to be dose independent, time-dependent and plasma membrane GLUT4 expression-dependent. Moreover, SDF7 are observed to be able to suppress TNF-α and leptin expressions that were mediated by 3T3-F442a adipocytes, while stimulated adiponectin secretion on the cells. There was a significant expression (p<0.01) of protein kinase C and small G protein TC10 on 3T3-F442a adipocytes upon treatment with SDF7 as compared to the control. SDF7 was also found to be effective in stimulating adiponectin and PPAR-γ mRNA upregulation at 50 µg/ml.

Conclusion

SDF7 exhibited good lipogenesis, adiponectinesis and glucose uptake stimulatory properties on 3T3-F442a adipocytes.  相似文献   
122.
罗扬拓  朱承睿  武元 《医学综述》2011,17(12):1781-1783
随着人们生活水平的提高,非酒精性脂肪性肝病(NAFLD)的发病率呈明显上升趋势。目前有关NAFLD的发生机制尚未完全阐明,普遍认为胰岛素抵抗(IR)是NAFLD发生的关键环节之一,大量研究表明脂肪细胞因子与IR关系密切,并可通过参与IR等途径来影响NAFLD的发生、发展,深入了解脂肪细胞因子与IR在NAFLD中的作用,对NAFLD的防治尤为重要。  相似文献   
123.
AIM:To investigate the effects of the Chinese herbal decoction,Yi-Qi-Zeng-Min-Tang(YQZMT),on insulin resistance in type 2 diabetic rats.METHODS:Sprague-Dawley rats were divided into two dietary regiments by feeding either normal pellet diet(NPD) or high fat diet(HFD).Four weeks later,the HFD-fed rats were injected intraperitoneally with lowdose streptozotocin(STZ).Rats with non-fasting blood glucose level ≥ 16.67 mmol/L were considered type 2 diabetic and further divided into five subgroups:the type 2 diabe...  相似文献   
124.
Background and aimObesity can be considered a state of chronic, low-grade inflammation. Particularly, visceral adipose tissue (VAT) seems to be an active compartment in pro-inflammatory molecule secretion. The possible existence of a correlation between circulating cytokines, their soluble receptors, abdominal fat accumulation and echocardiographic abnormalities in uncomplicated obesity was investigated.Methods and resultsEchocardiographic parameters, C-reactive protein (CRP), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6-R), tumor necrosis factor-α (TNF-α) and soluble TNF receptor I (TNFR-I) were assessed in 27 normotensive obese women (age 33.3 ± 8.3 years; BMI 43.5 ± 4.8 kg/m2) and 15 normal-weight controls (age 36.8 ± 8.2 years; BMI 22.6 ± 1.7 kg/m2). VAT was assessed by CT. The obese patients had higher serum IL-6 (p < 0.01), sIL-6-R (p < 0.0001), sIL-6-R/IL-6 complex (p < 0.05), TNF-α (p < 0.02), sTNF-α-RI (p < 0.03) and CRP (p < 0.0001) levels than normal women. Moreover, end-diastolic septum thickness (SW), end-diastolic posterior wall thickness (PW), absolute and indexed left ventricular mass, deceleration time (DT), myocardial performance index (MPI) and isovolumetric relaxation time (IVRT) were correlated with sIL-6-R, sIL-6-R/IL-6 complex and CRP levels. Interestingly, sIL-6-R, sIL-6-R/IL-6 complex, CRP, SW, PW, DT and MPI were higher in patients with a VAT area >130 cm2 than those with <130 cm2.ConclusionIn normotensive obese women several pro-inflammatory molecules correlate with both echocardiographic abnormalities and the amount of intra-abdominal fat; these results may support a role for visceral fat in predisposing to cardiac dysfunction, possibly through a low-grade state of inflammation.  相似文献   
125.
Lipid-lowering therapy is associated with reduced cardiovascular risk. The aim of the present study was to investigate whether lipid-lowering therapy might be associated with changes in the concentrations of metabolically important hormone concentrations. We performed a randomised cross-over open-label trial with atorvastatin (10 mg/day) and fenofibrate (200 mg/day), each for 6 weeks separated by a 6-week washout period in 13 patients (5 men, 8 women, age 60.0±6.8 years, body mass index 30.0±3.0 kg/m2) with type 2 diabetes mellitus and mixed hyperlipoproteinaemia. Plasma ghrelin (RIA, Phoenix Pharmaceuticals, Mountain View, CA, USA), adiponectin (ELISA, Biovendor, Heidelberg, Germany) as well as resistin (ELISA, Linco Research, St. Charles, MO, USA) concentrations were measured before and after atorvastatin as well as before and after fenofibrate. Ghrelin (462±84 pg/ml before vs. 464±102 pg/ml after atorvastatin, n.s.; 454±85 pg/ml before vs. 529±266 pg/ml after fenofibrate, n.s.), resistin (24.4±7.4 pg/ml before vs. 23.7±9.1 pg/ml after atorvastatin, n.s.; 23.4±8.2 pg/ml before vs. 19.9±5.5 pg/ml after fenofibrate, n.s.), adiponectin (10.89±5.33 pg/ml before vs. 12.41±5.75 pg/ml after atorvastatin, n.s.; 12.58±9.87 pg/ml before vs. 10.27±5.23 pg/ml after fenofibrate, n.s.) and insulin levels did not change significantly during lipid-lowering therapy. In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels.  相似文献   
126.
AimsAdipose tissue is considered as an endocrine organ that releases bioactive factors known as adipokines which contribute to the pathogenesis of rotundity-linked metabolic and cardiovascular complications. Rotundity is a major predisposer for the development and progression of coronary artery disease (CAD).Data synthesisThe literature survey from various databases such as Pubmed/Medline, DOAJ, Scopus, Clarivate analytics/Web of Science and Google Scholar were used to prepare this article. The epidemic of rotundity has gained significant attention to understand the biology of adipocytes and the metabolism of adipose tissue in obese individuals. In CAD, visfatin/NAMPT was primarily indicated as a clinical marker of atherosclerosis, endothelial dysfunction and vascular injury having a prognostic significance. Visfatin/NAMPT is a factor that promotes vascular inflammation and atherosclerosis. Omentin is an anti-inflammatory and anti-atherogenic adipokine regulating cardiovascular functions.ConclusionsThis review highlights and summarizes the scientific information pertaining to the role of the adipokines - omentin and visfatin in CAD.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号